{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T11:58:44Z","timestamp":1754481524164},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1097\/mph.0000000000001010","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T19:58:55Z","timestamp":1513108735000},"page":"163-168","source":"Crossref","is-referenced-by-count":7,"title":["Gemtuzumab Ozogamicin Containing Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Children"],"prefix":"10.1097","volume":"40","author":[{"given":"Anthony Pak-Yin","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine Queen Mary Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex Wing-Kwan","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Paediatrics Prince of Wales Hospital Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Ka-Leung","family":"Cheuk","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine Queen Mary Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Paediatrics Prince of Wales Hospital Hong Kong"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shau-Yin","family":"Ha","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine Queen Mary Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/cncr.22385","article-title":"Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia","volume":"109","author":"Rubnitz","year":"2007","journal-title":"Cancer"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/sj.leu.2401254","article-title":"Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial","volume":"13","author":"Webb","year":"1999","journal-title":"Leukemia (08876924)"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/leu.2010.127","article-title":"Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials","volume":"24","author":"Sander","year":"2010","journal-title":"Leukemia"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood.V86.8.3097.3097","article-title":"Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87","volume":"86","author":"Creutzig","year":"1995","journal-title":"Blood"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","article-title":"Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia","volume":"106","author":"Arceci","year":"2005","journal-title":"Blood"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1471-2407-6-172","article-title":"Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed\/refractory myeloid leukemia","volume":"6","author":"Brethon","year":"2006","journal-title":"BMC Cancer"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2141.2008.07370.x","article-title":"Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia","volume":"143","author":"Brethon","year":"2008","journal-title":"Br J Haematol"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0091270004267595","article-title":"Pharmacokinetics of gemtuzumab ozogamicin as a single\u2010agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia","volume":"44","author":"Buckwalter","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1182\/blood-2002-07-1947","article-title":"Gemtuzumab ozogamicin: first clinical experiences in children with relapsed\/refractory acute myeloid leukemia treated on compassionate-use basis","volume":"101","author":"Zwaan","year":"2003","journal-title":"Blood"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000075606","article-title":"Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia","volume":"27","author":"Reinhardt","year":"2004","journal-title":"Oncol Res Treat"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2141.2009.08011.x","article-title":"Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study","volume":"148","author":"Zwaan","year":"2010","journal-title":"Br J Haematol"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(97)09214-3","article-title":"Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial","volume":"351","author":"Burnett","year":"1998","journal-title":"Lancet"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood-2012-03-416701","article-title":"Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004","volume":"120","author":"Hasle","year":"2012","journal-title":"Blood"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood.V108.11.2013.2013","article-title":"Relapsed acute myeloid leukemia in children and adolescents: interim report of the international randomised phase III study relapsed AML 2001\/01","volume":"108","author":"Kaspers","year":"2006","journal-title":"Blood"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.leu.2404434","article-title":"High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group","volume":"21","author":"Taksin","year":"2006","journal-title":"Leukemia"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.leukres.2005.02.005","article-title":"Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia","volume":"29","author":"Chevallier","year":"2005","journal-title":"Leukemia Res"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1200\/JCO.2007.13.0096","article-title":"Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group","volume":"26","author":"Aplenc","year":"2008","journal-title":"J Clin Oncol"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2141.2009.07750.x","article-title":"Dismal long\u2010term prognosis for children with refractory acute myeloid leukaemia treated with gemtuzumab ozogamicin and stem cell transplantation: where now?","volume":"146","author":"Sibson","year":"2009","journal-title":"Br J Haematol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V116.21.1075.1075","article-title":"Gemtuzumab ozogamicin in refractory childhood acute myeloid leukemia","volume":"116","author":"Reinhardt","year":"2010","journal-title":"Blood"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"7164s","DOI":"10.1158\/1078-0432.CCR-1004-0018","article-title":"Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia","volume":"11","author":"Roman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"e2012072","DOI":"10.4084\/mjhid.2012.072","article-title":"Ara-C, idarubicine and gentuzumab ozogamicin (AIM) as salvage treatment in advanced acute myeloid leukemia patients","volume":"4","author":"Capria","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1200\/JCO.2007.15.9764","article-title":"Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukemia","volume":"26","author":"Chevallier","year":"2008","journal-title":"J Clin Oncol"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1200\/JCO.2009.26.7930","article-title":"Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia","volume":"28","author":"Filanovsky","year":"2010","journal-title":"J Clin Oncol"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/cncr.25554","article-title":"Improved outcome of patients with low\u2010and intermediate\u2010risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine","volume":"117","author":"Prebet","year":"2011","journal-title":"Cancer"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201803000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T17:19:23Z","timestamp":1719681563000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201803000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001010","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}